Short answer: there is no measured weight loss figure for 7.5 mg, because no trial used it
No pivotal Zepbound trial had a 7.5 mg arm, so no average weight loss has ever been measured at that dose. In the trial the label uses for its main weight results, 2,539 adults were randomly assigned to 5 mg, 10 mg, 15 mg or placebo. In the second, people with type 2 diabetes were assigned to 10 mg, 15 mg or placebo. Any number attached to 7.5 mg is interpolated between neighbouring arms or drawn from a clinic's own patients. What the evidence does give you is the bracket around it: at 72 weeks the mean weight change was 15.0% at 5 mg and 19.5% at 10 mg, and the share of people losing at least 20% of their body weight went from 30.0% to 50.1% across that same step.
The trial table, with the gap left visible
Here is the weight data the Zepbound label reports at week 72, taken from Study 1, the trial of 2,539 adults with obesity or overweight and no type 2 diabetes. The 7.5 mg row is in the table because leaving it out would hide the point. It is empty because the trial had nothing to put in it.
| Weekly dose | Trial arm? | Mean weight change at 72 weeks | Lost at least 10% | Lost at least 15% | Lost at least 20% |
|---|---|---|---|---|---|
| Placebo | Yes, n=643 | -3.1% | 18.8% | 8.8% | 3.1% |
| 5 mg | Yes, n=630 | -15.0% | 68.5% | 48.0% | 30.0% |
| 7.5 mg | No arm, in this or any other pivotal trial | Not measured | Not measured | Not measured | Not measured |
| 10 mg | Yes, n=636 | -19.5% | 78.1% | 66.6% | 50.1% |
| 15 mg | Yes, n=630 | -20.9% | 83.5% | 70.6% | 56.7% |
The second trial the label uses for weight, Study 2, enrolled 938 adults with type 2 diabetes and randomised them to 10 mg, 15 mg or placebo. Again no 7.5 mg arm. The two sleep apnea trials used the maximum tolerated dose, 10 mg or 15 mg. The randomised withdrawal trial used the maximum tolerated dose too. Across the entire pivotal programme, 7.5 mg was never an assigned dose.
Why the halfway guess is the wrong shape
The tempting move is to split the difference and call 7.5 mg roughly 17%. The trial data says that assumption is built on a curve that is not straight.
Going from 5 mg to 10 mg moved the mean by 4.5 percentage points. Going from 10 mg to 15 mg, the same 5 mg of additional drug, moved it by 1.4. The response curve flattens sharply as the dose rises, which means the steepest part of it is the stretch that 7.5 mg sits in. If the relationship over that lower stretch were closer to linear than the upper one, 7.5 mg would land nearer the middle of 15.0 and 19.5. If the flattening starts earlier, it would land higher. Nobody measured which, so both readings are guesses with the same evidence behind them: none.
The responder columns make the same point more usefully. The share of people losing at least 20% of their body weight went from 30.0% at 5 mg to 50.1% at 10 mg. That is a far larger relative jump than the means suggest, and it is the kind of difference a single average number hides. Whatever 7.5 mg does, it does it to a distribution, not to you specifically.
Where 7.5 mg does appear in the label
It appears in two places, and neither is the maintenance list.
- As a supplied strength. Zepbound comes in six: 2.5, 5, 7.5, 10, 12.5 and 15 mg, available as single-dose pens, single-dose vials, multi-dose vials and the KwikPen.
- As an escalation step. The label starts at 2.5 mg for 4 weeks, moves to 5 mg, and then allows increases in 2.5 mg increments after at least 4 weeks on the current dose. 7.5 mg is the first of those increments.
Where it does not appear is section 2.2. The recommended maintenance dosages for weight reduction and long-term maintenance are 5 mg, 10 mg and 15 mg. For obstructive sleep apnea they are 10 mg and 15 mg. 7.5 mg is on neither list, and nor is 12.5 mg. A prescriber can still keep you there, and many do, but it is a step the document describes rather than a destination it names.
What else moves when the dose goes up
The dose decision is not only about the weight column, and the other columns do not all point the same way.
| Dose | Severe gastrointestinal adverse reactions | Discontinued study drug in Study 1 |
|---|---|---|
| Placebo | 1% | 26.4% |
| 5 mg | 1.7% | 14.3% |
| 10 mg | 2.5% | 16.4% |
| 15 mg | 3.1% | 15.1% |
Severe gastrointestinal reactions rose steadily with dose, roughly doubling from 5 mg to 15 mg. Discontinuation did not follow the same line: it was highest on placebo, at 26.4%, and sat between 14% and 17% across all three active doses with no clean dose relationship. People left the trial because nothing was happening at least as often as because something was.
How to judge 7.5 mg for yourself, since the trials will not
With no trial arm to compare yourself to, the only data that answers the question is your own, and it has to be collected before the appointment that uses it, not reconstructed at it.
- Give it at least 4 weeks. That is the minimum the label itself requires before an increase, and it is the unit the escalation schedule works in. A fortnight tells you about side effects, not about effect.
- Judge the trend, not the reading. Weigh on the same day, the same way, and compare the slope across four to eight weeks. Single readings move more than the thing you are trying to measure.
- Mark every late or missed week. A dose taken three days late and a dose that stopped working look identical on a weight chart and have opposite answers.
- Score the gastrointestinal symptoms week by week. This is the explicit trade-off the label hands your prescriber: consider treatment response and tolerability when selecting the maintenance dosage. Half of that sentence is about how you feel, and it is the half nobody writes down.
- Bring the question, not the conclusion. "Four weeks at 7.5 mg, down 1.4 kg, nausea gone by week two" is a sentence a prescriber can act on. "I think it has stopped working" is not.
Frequently asked questions
How much weight will I lose on Zepbound 7.5 mg?
There is no trial figure, because 7.5 mg was never a randomised arm in the Zepbound programme. The doses either side of it were measured: at 72 weeks the mean weight change was 15.0% at 5 mg and 19.5% at 10 mg, against 3.1% on placebo. Your own result depends on far more than the strength, which is why the label tells prescribers to consider treatment response as well as dose.
Is 7.5 mg a maintenance dose of Zepbound?
Not one the label names. Section 2.2 lists 5 mg, 10 mg and 15 mg as the recommended maintenance dosages for weight reduction and long-term maintenance, and 10 mg or 15 mg for obstructive sleep apnea. 7.5 mg is a supplied strength and an escalation step, reached by increasing in 2.5 mg increments after at least 4 weeks on the current dose. The same is true of 12.5 mg.
Should I stay on 7.5 mg or move up to 10 mg?
That is your prescriber's decision, and the label gives them the two inputs: treatment response and tolerability. What the data can tell you is the scale of what is on the table. Moving from 5 mg to 10 mg changed the mean by 4.5 percentage points, while 10 mg to 15 mg changed it by 1.4, and severe gastrointestinal adverse reactions rose from 1.7% to 2.5% to 3.1% across those three doses.
Why do some websites quote a weight loss number for 7.5 mg?
Because interpolating between the 5 mg and 10 mg results produces a plausible-looking figure. The problem is the shape of the curve: the response flattens as the dose rises, so the gap between 5 and 10 mg is more than three times the gap between 10 and 15 mg. Where 7.5 mg falls inside that steeper stretch was never measured, so a midpoint is a guess presented as a result.
Is Zepbound 7.5 mg available in all the pen and vial types?
Yes. All six strengths, 2.5, 5, 7.5, 10, 12.5 and 15 mg, are supplied as single-dose pens and single-dose vials, and the multi-dose vial and KwikPen presentations each carry four doses at those strengths.
Does 7.5 mg work for obstructive sleep apnea?
The label does not name it for that indication. For moderate to severe obstructive sleep apnea in adults with obesity, the recommended maintenance dosages are 10 mg or 15 mg, and both sleep apnea trials used the maximum tolerated dose of 10 mg or 15 mg rather than a fixed lower strength.
How long should I stay at 7.5 mg before deciding?
The label allows an increase only after at least 4 weeks on the current dose, so 4 weeks is the minimum the document works in. Judging a plateau reliably takes longer, because week to week weight variation is larger than the trend you are reading.
Related reading
- Zepbound maintenance dose after goal weight, for the three dosages the label actually names
- Why increase the Zepbound dose?, for the one reason the label gives for the escalation schedule
- How long does Zepbound take to work?, for the three different clocks behind these 72 week figures
- Tirzepatide maintenance dose after weight loss, including the 2026 trial on stepping down
- How to reduce Zepbound side effects, for the tolerability half of the dose decision
- Zepbound reviews, patient ratings set against the same trial data
- Tracking tirzepatide injections, for recording the four weeks this decision needs
- Not losing weight on Zepbound 15 mg, what the trial recorded at the top of the ladder, where escalation runs out
Sources
- ZEPBOUND (tirzepatide) US prescribing information, Eli Lilly and Company. Section 14.1 for the Study 1 and Study 2 designs and the week 72 results table, section 2.1 for the escalation schedule and the 2.5 mg increments, section 2.2 for the recommended maintenance dosages for weight reduction and for obstructive sleep apnea, section 3 for the six supplied strengths and the four presentations, section 5.2 for the severe gastrointestinal adverse reaction rates by dose.
- ZEPBOUND label on DailyMed, US National Library of Medicine, for an independently hosted copy of the same label, including Table 2 of the week 72 weight results and the Study 1 discontinuation rates.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID 35658024. The published report of Study 1, the trial registered as NCT04184622, whose arms were 5 mg, 10 mg, 15 mg and placebo.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID 38078870. The randomised withdrawal trial, which used the maximum tolerated dose of 10 mg or 15 mg rather than a fixed strength.
This page summarises published prescribing information and peer-reviewed trial results for general education. It is not medical advice and it contains no dosing recommendation. It deliberately does not estimate a weight loss figure for 7.5 mg, because none has been measured. Which strength you take, and for how long, is a decision for your prescriber. Never start, stop or change a prescribed medicine on the basis of a web page.
Jabby is free on the App Store and keeps each dose, the date it went in, the site it went into and the days of nausea that followed on one timeline, which is the only trial data that exists for the strength you are actually on.